Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H29NO5S |
Molecular Weight | 431.545 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@H](O)C1=CC=C(C=C1)N2[C@@H](COCC3=CC=C(S3)C(O)=O)CCC2=O
InChI
InChIKey=NGKFLYGSJDSBQC-QUCCMNQESA-N
InChI=1S/C23H29NO5S/c1-2-3-4-5-20(25)16-6-8-17(9-7-16)24-18(10-13-22(24)26)14-29-15-19-11-12-21(30-19)23(27)28/h6-9,11-12,18,20,25H,2-5,10,13-15H2,1H3,(H,27,28)/t18-,20+/m1/s1
Simenepag isopropyl (AGN-210669) is an ophthalmic solution with potential intraocular pressure (IOP) lowering effects. Although the mechanism of action has not been disclosed, it is likely to be a sustained-release formulation of the EP agonist, AGN-210961. Simenepag isopropyl has been used in trials studying the treatment of ocular hypertension and open-angle glaucoma.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01001195
Drug: Simenepag isopropyl (AGN-210669) ophthalmic solution, 0.1%
One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Drug: AGN-210669 ophthalmic solution, 0.075%
One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Drug: AGN-210669 ophthalmic solution, 0.05%
One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.freepatentsonline.com/y2007/0203222.html
Simenepag (AGN-210676) is a selective prostaglandin EP2 agonist with EC50 of 5 nM. It is a less potent agonist for recombinant human prostaglandin receptors hEP3A and hDP with EC50s of 153 nM and 7749 nM, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
910562-15-1
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
V0LI771S16
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
XX-84
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
DTXSID90238395
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
9240
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
24759842
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103859
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
C152362
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY | |||
|
300000034362
Created by
admin on Fri Dec 15 19:47:04 GMT 2023 , Edited by admin on Fri Dec 15 19:47:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)